Introduction
The prevalence of the human immunodeficiency viruses (HIV) in pregnant women in inner London has apparently risen steadily since 1990 to 0.28%, the rate being slightly lower (0.08%) in outer London (Unlinked Anonymous Surveys Steering Group, 1995) . It is estimated that only 19% of HIV infected women in London and the South East are aware that they are infected. Fortunately, the prevalence of HIV in pregnant women outside London and at other sites such as Edinburgh and Dundee is low. Whereas there is an expanding database on HIV in pregnant women, less is known of infected women with gynaecological problems, including infertility. Currently, all prospective gamete donors in the UK are required to have an HIV test conducted in clinics licensed and inspected by the Human Fertilisation and Embryology Authority (HFEA) in accord with the legal requirements of the Human Fertilisation and Embryology Act 1990. Whereas spermatozoa from prospective donors must be quarantined by cryopreservation for a minimum of 6 months prior to release following a further negative HIV test, by contrast, fresh oocyte donation is permitted by women who are HIV negative at the time of donation, as the risk of HIV in this population of women is considered to be extremely low. Currently, there are no widely agreed guidelines on the management of couples or individuals who know they are seropositive for HIV or who have been identified as seropositive on routine screening. Consequently, practices and attitudes vary: some centres offer HIV screening only for those who are thought to be at risk; others require HIV screening, a negative result being a condition of acceptance for treatment. Issues surrounding routine HIV screening of infertile couples and their treatment have been debated recently (Doyle and Delany, 1991; Editorial, 1996) but there is still little consensus, other than in relation to gamete donation. Furthermore, a workshop entitled 'HIV testing and subfertilitywho should we treat?' was conducted at the HFEA 6th Annual Conference in London on 27 September 1996. We present here the results of a postal questionnaire sent to 70 fertility clinics, licensed by the HFEA, in November 1995 requesting information about routine screening for HIV and attitudes towards treatment of HIV positive individuals and couples.
Materials and methods
A postal questionnaire (Table I) 
Results
Fifty-eight of the 70 units licensed by the HFEA responded to the questionnaire. The response to questions concerning routine screening for HIV and some other conditions (hepatitis B and C) in one or both partners is summarized in Table II . Of 58 centres, 23 only performed routine screening for HIV in both partners, 24 for hepatitis B and eight for hepatitis C. Treatments offered in the event of a positive result are summarized in Table III . Nineteen centres stated that treatment would not be provided if either of the couple was HIV positive. Twenty-one centres stated that if the male was HIV positive, the following treatments would be offered: donor insemination (DI), 21 centres; intrauterine insemination (IUI) after sperm washing, one centre; and IVF, one centre. By contrast, if the woman was HIV positive, 38 centres would not provide treatment, 13 were uncertain whether they would, three centres IVF ϭ in-vitro fertilization, IUI ϭ intrauterine insemination, OI ϭ ovulation induction, DI ϭ donor insemination. would provide IVF, two centres IUI and two centres would refer the matter to the Ethics Committee. Nine centres had already provided fertility treatment for couples in which the male was HIV positive and two centres had provided fertility treatment to HIV positive women.
Discussion
Our survey describes for the first time some of the approaches of UK Fertility Centres licensed by the HFEA towards the provision of routine screening for HIV, and treatment if an HIV positive result is determined. Less than half the fertility clinics that responded to the questionnaire offer routine screening for HIV, hepatitis B and hepatitis C prior to treatment. UK fertility practice is required to adhere to the HFEA stipulation that an assessment should be made of the welfare of the unborn child. This may include consideration of the risk of vertical HIV transmission and the possible premature death of one or both parents from HIV-related pathology. Although only two centres had treated couples in which the female partner was infected with HIV, nine had treated couples where the male partner was HIV positive. Guidelines in this area are now available from various sources. The European Society for Human Reproduction and Embryology (ESHRE) (1995) states that after counselling, screening for HIV antibodies should be included in a fertility clinic protocol, but makes no recommendations on the future treatment of those found to be HIV infected. The American Society for Reproductive Medicine (American Ethics Committee of the Fertility Society, 1994) has suggested routine HIV testing for all couples prior to fertility treatment and states that although proceeding with fertility treatment in HIV infected individuals is not necessarily unethical, HIV infection is a serious contraindication to further treatment. Emphasis was placed on each fertility centre having a written policy documenting its approach to HIV and assisted reproduction. The FIGO Committee for the study of Ethical Aspects of Human Reproduction recently published guidelines entitled AIDS and Human Reproduction (Schenker, 1997) stating that 'to protect the interest of those at risk of unwanted exposure to HIV including the potential child, only seronegative individuals should be allowed to participate'. The Fertility Society of Australia has not developed any guidance on the issues but has stated that known HIV positive patients have not been offered treatment at any of its licensed centres (Kay, 1995, personal communication) . Fertility treatment of HIV infected women is a contentious issue as evidenced by recent debate (Editorial, 1996) . Given that not all centres offer HIV testing and that a majority of HIV positive women in the UK are unaware of their infection, it is inevitable that a small number of unrecognized infected women will be offered fertility treatment. In addition, HIV positive women seeking fertility treatment may not declare their condition, fearing that treatment may not be available or may be withdrawn. The risk of vertical transmission of HIV from mother to child has been variously reported, and ranges from 16% in the European Collaborative Study (1992) up to 45% in some African studies (Ryder et al., 1989) . Over the past 2 years, interventions to reduce vertical transmission (Royal College of Obstetricians & Gynaecologists, 1990) , including the use of zidovudine in pregnancy and labour (Connor et al., 1994) and the avoidance of breastfeeding (Dunn et al., 1992) have been shown to be effective. Women contemplating pregnancy need to be aware of this information to make informed choices concerning HIV testing in and around the time of pregnancy.
Our survey suggests that HIV testing policies and treatment decisions vary widely between fertility centres in the UK. As the rate of HIV infection in the UK population of women of child-bearing age inexorably increases, it will become ever more important to produce clear guidance on the issues involved, to allow clinicians and patients to make appropriate decisions about their future and that of their children.
Requesting an HIV test as a prerequisite for inclusion in an IVF programme is not in accord with the guidelines for HIV testing in the UK. Furthermore, patients who are known to be HIV positive, or who fear they may be at risk of being HIV positive, may be inclined to seek treatment in centres which do not have such a policy, thus continuing to conceal their HIV positive status during possible pregnancy, and being excluded from active management to decrease the risk of vertical transmission to their child.
The lack of availability of HIV counselling prior to fertility treatment does not comply with the HFEA guidelines that the welfare of the unborn child must be considered by licensed centres prior to IVF treatment. It is also a patient's right to be adequately informed of the risk of vertical transmission of the HIV virus from mother to child. Our observations have led us to conclude that (i) each centre should have a clear policy regarding HIV testing and treatment of HIV positive patients; (ii) the decision whether or not to be tested must not prejudice the patient's future relationship with the treatment centre, neither must it affect the normal progress of the treatment procedure; (iii) IVF treatment of a couple in whom the female partner is HIV positive is not acceptable as long as the risk of vertical transmission to the child cannot be substantially reduced; (iv) after extensive counselling, it seems acceptable to treat a couple where the male partner is HIV positive with insemination of his seronegative female partner with donor spermatozoa. The possibility of homologous sperm insemination after sperm washing is encouraging, but more data are needed before this treatment can be routinely offered. It is noteworthy that our centre is proceeding with the latter strategy on an individual case basis; (v) prior to any infertility treatment, all couples should be counselled and offered testing for HIV infection after informed consent has been signed; (vi) precautions to reduce the risk of transmission to other patients and members of staff during the different phases of the treatment must be routine practice for all patients, whether or not they have been HIV tested.
